Lukin DJ, Kumar A, Hajifathalian K, Sharaiha RZ, Scherl EJ, Longman RS.
2020.
Baseline Disease Activity and Steroid Therapy Stratify Risk of COVID-19 in Patients With Inflammatory Bowel Disease.. Gastroenterology. 159(4):1541-1544.e2.
Dogan B, Suzuki H, Herlekar D, R Sartor B, Campbell BJ, Roberts CL, Stewart K, Scherl EJ, Araz Y, Bitar PP et al..
2014.
Inflammation-associated adherent-invasive Escherichia coli are enriched in pathways for use of propanediol and iron and M-cell translocation.. Inflamm Bowel Dis. 20(11):1919-32.
Montrose DC, Scherl EJ, Bosworth BP, Zhou XKathy, Jung B, Dannenberg AJ, Hla T.
2013.
S1P₁ localizes to the colonic vasculature in ulcerative colitis and maintains blood vessel integrity.. J Lipid Res. 54(3):843-51.
Dassopoulos T, Cohen RD, Scherl EJ, Schwartz RM, Kosinski L, Regueiro MD.
2015.
Ulcerative Colitis Care Pathway.. Gastroenterology. 149(1):238-45.
Panaccione R, Danese S, Sandborn WJ, O'Brien CD, Zhou Y, Zhang H, Adedokun OJ, Tikhonov I, Targan S, Abreu MT et al..
2020.
Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy.. Aliment Pharmacol Ther. 52(11-12):1658-1675.